Literature DB >> 25553976

α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.

Dinesh S Bangari1, Karen M Ashe2, Robert J Desnick3, Colleen Maloney4, John Lydon4, Peter Piepenhagen4, Eva Budman2, John P Leonard2, Seng H Cheng2, John Marshall2, Beth L Thurberg4.   

Abstract

Fabry disease is an X-linked lysosomal storage disease caused by deficient activity of α-galactosidase A and the resultant systemic accumulation of globotrioasylceramide (GL-3) and related glycolipids. α-Galactosidase A gene knockout (Gla KO) mice have no α-galactosidase A activity and progressively accumulate GL-3 in tissues and fluids, similarly to FD patients. The nature and temporal effects of the progressive substrate accumulation on tissue histology in these mice have not previously been characterized. Here, we report the pathology of young to old (3 to 17 months old) Gla KO mice and compare these changes with those in strain-matched control animals. Gla KO mice accumulated GL-3 in various tissues and fluids with age. Lysosomal GL-3 inclusions increased with age in multiple cell types, including renal epithelial, intestinal, and vascular smooth muscle cells, and neurons in trigeminal and dorsal root ganglia, as detected by light and electron microscopy. However, unlike the case for male FD patients with the type 1 classic phenotype, GL-3 inclusions were not detected in vascular endothelial cells or cardiomyocytes. The histological changes in Gla KO mice better resemble the type 2 later-onset phenotype observed in patients with residual α-galactosidase A activity. GL-3 accumulation in the small intestine and sensory ganglia of Gla KO mice provides a model for study of enteropathy and neuropathy in Fabry disease.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25553976     DOI: 10.1016/j.ajpath.2014.11.004

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.

Authors:  Xing-Li Meng; Taniqua S Day; Nathan McNeill; Paula Ashcraft; Thomas Frischmuth; Seng H Cheng; Zhi-Ping Liu; Jin-Song Shen; Raphael Schiffmann
Journal:  J Inherit Metab Dis       Date:  2016-03-10       Impact factor: 4.982

2.  Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.

Authors:  Xuling Zhu; Ling Yin; Matt Theisen; Jenny Zhuo; Summar Siddiqui; Becca Levy; Vladimir Presnyak; Andrea Frassetto; Jaclyn Milton; Timothy Salerno; Kerry E Benenato; Joe Milano; Andy Lynn; Staci Sabnis; Kristine Burke; Gilles Besin; Christine M Lukacs; Lin T Guey; Patrick F Finn; Paolo G V Martini
Journal:  Am J Hum Genet       Date:  2019-03-14       Impact factor: 11.025

3.  Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.

Authors:  Siamak Jabbarzadeh-Tabrizi; Michel Boutin; Taniqua S Day; Mouna Taroua; Raphael Schiffmann; Christiane Auray-Blais; Jin-Song Shen
Journal:  J Lipid Res       Date:  2020-08-31       Impact factor: 5.922

Review 4.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

5.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.

Authors:  Karen M Ashe; Eva Budman; Dinesh S Bangari; Craig S Siegel; Jennifer B Nietupski; Bing Wang; Robert J Desnick; Ronald K Scheule; John P Leonard; Seng H Cheng; John Marshall
Journal:  Mol Med       Date:  2015-04-30       Impact factor: 6.354

Review 6.  Ion channels and pain in Fabry disease.

Authors:  Carina Weissmann; Adriana A Albanese; Natalia E Contreras; María N Gobetto; Libia C Salinas Castellanos; Osvaldo D Uchitel
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

7.  Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.

Authors:  Jarmila Lakomá; Roberto Rimondini; Antonio Ferrer Montiel; Vincenzo Donadio; Rocco Liguori; Marco Caprini
Journal:  Mol Pain       Date:  2016-08-16       Impact factor: 3.395

8.  Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.

Authors:  Hideaki Sueoka; Mikio Aoki; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

Review 9.  Electrocardiographic Changes and Arrhythmia in Fabry Disease.

Authors:  Mehdi Namdar
Journal:  Front Cardiovasc Med       Date:  2016-03-24

10.  Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.

Authors:  Nurcan Üçeyler; Lydia Biko; Dorothea Hose; Lukas Hofmann; Claudia Sommer
Journal:  Mol Pain       Date:  2016-05-04       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.